US-based medical device maker Uroplasty has announced that its offering of 1.5 million shares was priced at $3.50 each. The company plans to use the funds raised to expand its sales and marketing organizations.
Subscribe to our email newsletter
Uroplasty has granted the underwriters a 30-day option to purchase up to an additional 219,960 shares of common stock at the offering price to cover over-allotments. The proceeds from the sale of shares will be used primarily to expand its sales and marketing organization in the US, to conduct clinical studies to support its marketing efforts and for working capital purposes.
Craig-Hallum Capital is serving as bookrunning lead manager for the offering with Noble International Investments acting as co-manager.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.